Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
282 DKK | +1.81% | -0.35% | +125.60% |
Apr. 17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
Mar. 29 | Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. | CI |
Sales 2022 | 199M 28.59M | Sales 2023 | 205M 29.4M | Capitalization | 2.04B 292M |
---|---|---|---|---|---|
Net income 2022 | 4M 574K | Net income 2023 | -44M -6.31M | EV / Sales 2022 * | - |
Net cash position 2022 | 2.52M 362K | Net cash position 2023 | 386M 55.35M | EV / Sales 2023 | 8.05 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-42.6
x | Employees | 220 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.58% |
1 day | +1.81% | ||
1 week | -0.35% | ||
Current month | -3.09% | ||
1 month | +8.46% | ||
3 months | +133.06% | ||
6 months | +179.26% | ||
Current year | +125.60% |
Managers | Title | Age | Since |
---|---|---|---|
Niels Vrang
FOU | Founder | 56 | 07-12-31 |
Henrik Blou
CEO | Chief Executive Officer | 45 | 16-05-31 |
Kristian Borbos
DFI | Director of Finance/CFO | 46 | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 58 | 21-12-31 | |
Director/Board Member | 48 | 21-12-31 | |
Jacob Jelsing
FOU | Founder | 50 | 07-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 282 | +1.81% | 9,608 |
24-04-25 | 277 | -5.78% | 20,869 |
24-04-24 | 294 | +0.34% | 17,403 |
24-04-23 | 293 | +3.53% | 20,489 |
24-04-22 | 283 | 0.00% | 8,653 |
Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 10:59 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+125.60% | 658M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- GUBRA Stock